RMTI

Rockwell is a low-margin, no-moat commodity manufacturer of hemodialysis concentrates, and FY2025 exposed the fragility of the model. Revenue collapsed 31.8% from a $101M FY2024 peak to $69.3M, and net income swung back to a -$5.31M loss after finally nearing breakeven (-$480K) in FY2024. The MD&A names the culprit: DaVita 'significantly reduced its product purchases,' and FY2025 revenue was flattered by $2.0M of quarterly non-refundable payments booked straight to the top line to 'ensure supply continuity.' The Second Amendment only extends the DaVita relationship to Dec 31, 2026, and DaVita has already 'indicated that it would completely transition to another supplier' — so the largest customer is a wasting asset, not a base.

The economics are thin and worsening: 16.9% gross margin, -6.8% operating margin, -14.4% ROE, and negative operating cash flow (-$659K). Management cut R&D expense to $0, confirming there is no pipeline to re-rate on — this is purely a concentrates distributor competing against Fresenius (vertically integrated, ~37% of U.S. in-center hemodialysis patients, and which 'has routinely acquired our customers') and Nipro, both vastly larger and using bundling/low pricing that Rockwell cannot match with no broader renal portfolio. Closing the South Carolina plant signals cost defense, not growth. A -$403M accumulated deficit is the honest scorecard of this franchise.